Successful closing of the CHF 14 million Series B2 of hemotune under the lead of Belmondo and with the participation of OCCIDENT, as well as existing and new investors.
A peer-reviewed article on Resistell's rapid phenotypic solution for antibiotic susceptibility testing (AST) has been published in Nature Communications.
OCCIDENT invests in the Finnish company Chipmetrics, which sets a new standard for the semiconductor industry by developing and manufacturing innovative metrology chips and wafers.